Literature DB >> 15191635

Pulmonary thromboembolism superimposed on a congenital ventricular septal defect in a 50-year-old man inhaled nitric oxide and sildenafil to the rescue.

Gregory D Lewis1, Kenneth D Bloch, Marc J Semigran.   

Abstract

We report the combined use of inhaled nitric oxide (iNO) and sildenafil to selectively lower pulmonary vascular resistance (PVR) and reverse right-to-left shunt flow across a congenital ventricular septal defect (VSD) in a 50-year-old man. The patient developed right-to-left shunt flow with profound hypoxia because of an acute pulmonary embolism superimposed on underlying pulmonary hypertension. The dramatic improvement in oxygenation and PVR with sildenafil plus iNO has been sustained with sildenafil monotherapy. To our knowledge, use of this combination therapy in patients with decompensated pulmonary arterial hypertension (PAH) and a predisposition to right-to-left shunting has not been previously reported. Copyright 2004 Lippincott Williams and Wilkins

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191635     DOI: 10.1097/01.crd.0000122635.12743.57

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  3 in total

1.  Dramatic beneficial effects of sildenafil in recurrent massive pulmonary embolism.

Authors:  Vincent Ganière; François Feihl; Damien Tagan
Journal:  Intensive Care Med       Date:  2006-02-01       Impact factor: 17.440

Review 2.  Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.

Authors:  Gregory D Lewis; Marc J Semigran
Journal:  Curr Heart Fail Rep       Date:  2004-12

3.  ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs.

Authors:  Carol Reinero; Lance C Visser; Heidi B Kellihan; Isabelle Masseau; Elizabeth Rozanski; Cécile Clercx; Kurt Williams; Jonathan Abbott; Michele Borgarelli; Brian A Scansen
Journal:  J Vet Intern Med       Date:  2020-02-17       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.